COMPUMEDICS LIMITED — Capital/Financing Update 2025

Oct 22, 2025

==> picture [280 x 67] intentionally omitted <==

ASX Release 23[rd] October 2025

Cleansing Notice

This notice is given by Compumedics Limited (Compumedics) under section 708A(5)(e) and 708A(6) of the Corporations Act 2001 (the Act).

On 23 October 2025, Compumedics issued to Australian institutional investors 7,543,860 fully paid ordinary shares (ASX Code: CMP) (the Shares) at AU$0.285 per share.

The Shares are in a class of securities that were quoted on the Australian Securities Exchange at all times in the last three months before the date on which they were issued.

Compumedics gives notice pursuant to section 708A(5)(e) of the Act in connection with the shares referred to above.

Compumedics issued the shares without disclosure to the investors under Part 6D.2 of the Act.

As at the date of this notice, Compumedics has complied with:

1. the provisions of Chapter 2M of the Act as they apply to Compumedics; and

2. sections 674 and 674A of the Act.

As at the date of this notice, there is no excluded information as described in sections 708A(7) and 708A(8) of the Act.

Dated: 23 October 2025

David Lawson

Company Secretary

About Compumedics Limited

Compumedics Limited [ASX: CMP] is a leading global medical device company that develops, manufactures, and commercialises diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring applications. The Company owns Neuroscan, based in the US, and DWL Elektronishe GmbH, based in Germany. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe, and the Middle East.

Executive Chairman Dr. David Burton founded Compumedics in 1987. The same year, the Company successfully designed and installed the first fully computerised Australian sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on developing products for the growing international sleep clinic and home monitoring markets.

Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia’s Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian Governments.

For further information, please contact:

Dr. David Burton David Lawson Executive Chairman, CEO Director, CFO P: +61 3 8420 7300 P: + 61 3 8420 7300 F: +61 3 8420 7399 F: +61 3 8420 7399

Authorised for lodgement by Compumedics Limited’s Board of Directors